Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer

Clinical and Experimental Metastasis

Volumn 18, Issue 7, 2000, Pages 539-545

  Ichiki, Katsuyuki ^a   Mitani, Noriyasu ^a   Doki, Yoshinori ^b   Hara, Hiroiku ^b   Misaki, Takuro ^b   Saiki, Ikuo ^a  

^a Toyama Medical and Pharmaceutical University   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Activator protein 1 (AP 1); Lewis lung carcinoma (LLC); Mediastinal lymph node metastasis; u PA receptor (u PAR); Urokinase type plasminogen activator (u PA)

Indexed keywords

CISPLATIN; CURCUMIN; MESSENGER RNA; TRANSCRIPTION FACTOR AP 1; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER TRANSPLANTATION; CELL ISOLATION; CELL SURVIVAL; DOSE RESPONSE; FEMALE; GENETIC TRANSCRIPTION; LUNG CANCER; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MEDIASTINUM METASTASIS; MOUSE; NONHUMAN; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CELL DIVISION; CISPLATIN; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; KINETICS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MEDIASTINAL NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; RECEPTORS, CELL SURFACE; RNA, NEOPLASM; TRANSCRIPTION FACTOR AP-1; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034787966     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011980313237     Document Type: Article

References (48)

1. Lung cancer
2. Cancer of the lung
3. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis
4. 'Tumor volume' as a predictor of survival after resection of non-small-cell lung cancer (NSCLC)
5. Revisions in the international system for staging lung cancer
6. Survival and prognostic factors in resected N2 non-small cell lung cancer: A study of 140 cases. Leuven lung cancer group
7. Novel metastasis model of human lung cancer cells representing different histological types in SCID mice depleted of NK cells
8. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice
9. Irradiated nude rat model for orthotopic human lung cancers
10. Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice
11. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma
12. Plasminogen activator and their inhibitors in non-small cell lung cancer
13. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: Analysis by Northern blotting and in situ hybridization
14. TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma
15. Selection of successive tumor lines for metastasis
16. Modification of certain inflammation induced biochemical changes by curcumin
17. Antioxidant activity of curcumin and related compounds
18. Anti-metastatic activity of curcumin and catechin
19. Inhibition of fos-jun-DNA complex formation by dihydroguaiaretic acid and in vitro cytotoxic effects on cancer cells
20. Suppression of c-jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells
21. Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases
22. The nude mouse and anticancer drug evaluation
23. A modified and convenient method for assessing tumor cell invasion and migration and its application to screening for inhibitors
24. Plasminogen activator system in osteoclasts
25. Identification of cytokine and adhesion molecule mRNA in murine lung tissue and isolated T cell and eosinophils by semi-quantitative reverse transcriptase-polymerase chain reaction
26. Nonparametric estimation from incomplete observations
27. Functional characterization of COM, a DNA region required for cooperation between AP-1 sites in urokinase gene transcription
28. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene
29. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like like domain of urokinase in the experimental and spontaneous metastasis model
30. Effect of tranexamic acid and urokinase on hematogenous metastasis of Lewis lung carcinoma in mice
31. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model
32. Fos and Jun: The AP-1 connection
33. Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinoma
34. Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas
35. Okadaic acid-dependent induction of the urokinase-type plasminogen activator gene associated with stabilization and autoregulation of c-Jun
36. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells
37. Effect of EGF on prostate cancer cell line PC3 growth and invasion
38. Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction
39. Regulation of matrix metalloproteinase in tumor invasion
40. Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells
41. Functional characterization of the human basic fibroblast growth factor gene promoter
42. Curcumin inhibits cyclooxygenase-2 transcription in bile acid-and phorbol ester-treated human gastrointestial epithelial cells
43. Vascular endothelial growth factor overproduced by tumor cells acts predominantly as a potent angiogenic factor contributing to malignant progression
44. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas
45. Expression of cyclooxygenase-2 in human lung carcinoma
46. Combined modality therapy of lung cancer
47. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?